Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Change in Accured Expenses (2018 - 2025)

TransMedics (TMDX) has 8 years of Change in Accured Expenses data on record, last reported at $7.0 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 199.74% year-over-year to $7.0 million; the TTM value through Dec 2025 reached $17.7 million, up 122.9%, while the annual FY2025 figure was $17.7 million, 122.9% up from the prior year.
  • Change in Accured Expenses reached $7.0 million in Q4 2025 per TMDX's latest filing, down from $13.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $13.1 million in Q3 2025 and bottomed at -$4.6 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $2.4 million, with a median of $2.2 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: soared 86450.0% in 2023, then tumbled 9377.55% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.5 million in 2021, then skyrocketed by 36.76% to $3.4 million in 2022, then surged by 44.93% to $5.0 million in 2023, then tumbled by 53.45% to $2.3 million in 2024, then surged by 199.74% to $7.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $7.0 million in Q4 2025, $13.1 million in Q3 2025, and $2.2 million in Q2 2025.